ACD Labs Logo
MENU

Enabling Remote Working for R&D Organizations Impacted by the COVID-19 Pandemic

Many ACD/Labs software users are changing their schedules or are forced to work remotely due to the physical distancing and quarantine directions imposed due to the COVID-19 pandemic. Furthermore, travel restrictions have highlighted and emphasized the need for long distance collaboration. ACD/Labs' COVID-19 Response

ACD/Labs' COVID-19 Response

ACD/Labs is committed to providing our customers and partners with the same reliable and trustworthy service they have been accustomed to receiving over the years. Our quality assurance systems and practices, and risk mitigation policies, are in place to ensure redundancy and continued quality of service and support across our distributed staff and global locations.

We have recently conducted an assessment of our systems and practices in light of the Coronavirus Disease 2019 (COVID-19) outbreak and trust that they are sufficiently adequate to meet the needs of the present and evolving epidemiologic situation.

With that, we have stressed and continue to stress that the safety and health of our industry contacts, customers, partners, employees and other stakeholders are of paramount importance. By the very nature of our business as an internationally localized technology company, we are equipped to manage and sustain all necessary online communications and support channels. We will continue conducting our business via electronic communication means (videoconferences, webinars, etc.) in lieu of face-to-face interaction, as required, in accordance with WHO, local governments and our customer policies. We will continue to closely monitor policy and guidance changes and adjust our practices to assure conformance moving forward.

In addition to the information below, we have written a short guidance to support scientists in the transition to working remotely and using ACD/Labs' tools to help R&D organizations maintain productivity and assist in planning/readiness for resuming normal work activities.

Download the Whitepaper: Planning for Quarantine/Physical Distancing

Transition to Working Remotely with ACD/Labs Software

  1. Use Remote Desktop to access your computer in the lab or office.
  2. Benefit from complimentary license expansion to support employees working from home.
  3. Enable enterprise data and knowledge sharing, or silent automation to pull analytical data directly from instruments.

We're Still Here to Support and Assist You

As a global company with many employees usually working from home we do not expect disruption of services and support to our customers. Please continue to reach out and contact us with your needs and requirements.

ACD/Labs technical support staff are ready to assist you as usual.

Information for activating license keys can be found here.

If you are experiencing issues connecting to your license server from home (including issues with firewalls, VPN, and antivirus software), we recommend that you contact your internal IT department before requesting help from our support team.

Online Training & Webinars

With disruption to their usual activities, many of our customers have found this to be an ideal time to learn more about ACD/Labs software, and we're happy to support this.

Watch for updated information about online training sessions. We are also delivering several webinars in the coming weeks. Access registration for upcoming webinars and/or watch past webinars on-demand.

Resources

Andrew Anderson recently shared his insight on workflow automation trends in a Pharma Manufacturing article. He emphasizes taking a quality-first approach throughout the automation, digitalization, and analysis processes to truly realize the benefits of Industry 4.0. Here are some of the highlights.
Read more

Richard Lee reflects on how biotechnology organizations can use their historical data to address real chemistry world problems; especially during this time when more and more scientists are working remotely.
Read more

At a time when the world is watching and expecting lightening fast results from drug development for SARS-COV-2 therapies I am reflecting on the impediments drug development teams face in releasing an antiviral drug quickly while keeping safety and quality at the forefront.
Read more

Andrew Anderson shares some guidelines on how our software can support scientists shifting to a remote working environment.
Read more